САЩ - английски - NLM (National Library of Medicine)

american health packaging - pyrazinamide (unii: 2kni5n06ti) (pyrazinamide - unii:2kni5n06ti) - pyrazinamide 500 mg - pyrazinamide is indicated for the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents. (the current recommendation of the cdc for drug-susceptible disease is to use a six-month regimen for initial treatment of active tuberculosis, consisting of isoniazid, rifampin and pyrazinamide given for 2 months, followed by isoniazid and rifampin for 4 months. *4 ) (patients with drug-resistant disease should be treated with regimens individualized to their situation. pyrazinamide frequently will be an important component of such therapy.) (in patients with concomitant hiv infection, the physician should be aware of current recommendations of cdc. it is possible these patients may require a longer course of treatment.) it is also indicated after treatment failure with other primary drugs in any form of active tuberculosis. pyrazinamide should only be used in conjunction with other effective antituberculous agents. *see recommendations of center for disease con

САЩ - английски - NLM (National Library of Medicine)

department of state health services, pharmacy branch - pyrazinamide (unii: 2kni5n06ti) (pyrazinamide - unii:2kni5n06ti) - pyrazinamide 500 mg - pyrazinamide is indicated for the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents. (the current recommendation of the cdc for drug-susceptible disease is to use a six-month regimen for initial treatment of active tuberculosis, consisting of isoniazid, rifampin and pyrazinamide given for 2 months, followed by isoniazid and rifampin for 4 months. *4 ) (patients with drug-resistant disease should be treated with regimens individualized to their situation. pyrazinamide frequently will be an important component of such therapy.) (in patients with concomitant hiv infection, the physician should be aware of current recommendation of cdc. it is possible these patients may require a longer course of treatment). it is also indicated after treatment failure with other primary drugs in any form of active tuberculosis. pyrazinamide should only be used in conjunction with other effective antituberculous agents. *see recommendations of center for di

САЩ - английски - NLM (National Library of Medicine)

guangxi yulin pharmaceutical co ltd - camphor (synthetic) (unii: 5tjd82a1et) (camphor (synthetic) - unii:5tjd82a1et), menthol (unii: l7t10eip3a) (menthol - unii:l7t10eip3a) - camphor (synthetic) 5.5 g in 100 ml - purposes external analgesic external analgesic uses for the temporary relief of minor aches and pains of muscles and joints due to: simple backache arthritis strains bruises sprains do not use on wounds on irritated or damaged skin otherwise than as directed stop use and ask a doctor if condition worsens symptoms persist for more than 7 days symptoms clear up and occur again within a few days excessive irritation of the skin develops nausea, vomiting, abdominal discomfort, diarrhea, or skin rash occurs when using for pain of arthritis: pain persists for more than 10 days redness is present in conditions affecting children under 12 years of age

САЩ - английски - NLM (National Library of Medicine)

par pharmaceutical - pyrazinamide (unii: 2kni5n06ti) (pyrazinamide - unii:2kni5n06ti) - pyrazinamide 500 mg - pyrazinamide is indicated for the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents. (the current recommendation of the cdc for drug-susceptible disease is to use a six-month regimen for initial treatment of active tuberculosis, consisting of isoniazid, rifampin and pyrazinamide given for 2 months, followed by isoniazid and rifampin for 4 months.* 4 ) (patients with drug-resistant disease should be treated with regimens individualized to their situation. pyrazinamide frequently will be an important component of such therapy.) (in patients with concomitant hiv infection, the physician should be aware of current recommendations of cdc. it is possible these patients may require a longer course of treatment.) it is also indicated after treatment failure with other primary drugs in any form of active tuberculosis. pyrazinamide should only be used in conjunction with other effective antituberculous agents. *see recommendations of center for disease contr

САЩ - английски - NLM (National Library of Medicine)

remedyrepack inc. - pyrazinamide (unii: 2kni5n06ti) (pyrazinamide - unii:2kni5n06ti) - pyrazinamide 500 mg - pyrazinamide is indicated for the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents. (the current recommendation of the cdc for drug-susceptible disease is to use a six-month regimen for initial treatment of active tuberculosis, consisting of isoniazid, rifampin and pyrazinamide given for 2 months, followed by isoniazid and rifampin for 4 months.* 4 ) (patients with drug-resistant disease should be treated with regimens individualized to their situation. pyrazinamide frequently will be an important component of such therapy.) (in patients with concomitant hiv infection, the physician should be aware of current recommendations of cdc. it is possible these patients may require a longer course of treatment.) it is also indicated after treatment failure with other primary drugs in any form of active tuberculosis. pyrazinamide should only be used in conjunction with other effective antituberculous agents. *see recommendations of center for

САЩ - английски - NLM (National Library of Medicine)

a-s medication solutions - pyrazinamide (unii: 2kni5n06ti) (pyrazinamide - unii:2kni5n06ti) - pyrazinamide is indicated for the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents. (the current recommendation of the cdc for drug-susceptible disease is to use a six-month regimen for initial treatment of active tuberculosis, consisting of isoniazid, rifampin and pyrazinamide given for 2 months, followed by isoniazid and rifampin for 4 months.* 4 ) (patients with drug-resistant disease should be treated with regimens individualized to their situation. pyrazinamide frequently will be an important component of such therapy.) (in patients with concomitant hiv infection, the physician should be aware of current recommendations of cdc. it is possible these patients may require a longer course of treatment.) it is also indicated after treatment failure with other primary drugs in any form of active tuberculosis. pyrazinamide should only be used in conjunction with other effective antituberculous agents. *see recommendations of center for disease contr

САЩ - английски - NLM (National Library of Medicine)

major pharmaceuticals - pyrazinamide (unii: 2kni5n06ti) (pyrazinamide - unii:2kni5n06ti) - pyrazinamide is indicated for the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents. (the current recommendation of the cdc for drug-susceptible disease is to use a six-month regimen for initial treatment of active tuberculosis, consisting of isoniazid, rifampin and pyrazinamide given for 2 months, followed by isoniazid and rifampin for 4 months.* 4 ) (patients with drug-resistant disease should be treated with regimens individualized to their situation. pyrazinamide frequently will be an important component of such therapy.) (in patients with concomitant hiv infection, the physician should be aware of current recommendations of cdc. it is possible these patients may require a longer course of treatment.) it is also indicated after treatment failure with other primary drugs in any form of active tuberculosis. pyrazinamide should only be used in conjunction with other effective antituberculous agents. *see recommendations of center for disease contr

САЩ - английски - NLM (National Library of Medicine)

remedyrepack inc. - pyrazinamide (unii: 2kni5n06ti) (pyrazinamide - unii:2kni5n06ti) - pyrazinamide is indicated for the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents. (the current recommendation of the cdc for drug-susceptible disease is to use a six-month regimen for initial treatment of active tuberculosis, consisting of isoniazid, rifampin and pyrazinamide given for 2 months, followed by isoniazid and rifampin for 4 months. *4 ) (patients with drug-resistant disease should be treated with regimens individualized to their situation. pyrazinamide frequently will be an important component of such therapy.) (in patients with concomitant hiv infection, the physician should be aware of current recommendation of cdc. it is possible these patients may require a longer course of treatment). it is also indicated after treatment failure with other primary drugs in any form of active tuberculosis. pyrazinamide should only be used in conjunction with other effective antituberculous agents. *see recommendations of center for disease control (cdc) and american thoracic society for complete regimen and dosage recommendations. 4 pyrazinamide is contraindicated in persons: - with severe hepatic damage. - who have shown hypersensitivity to it. - with acute gout.

САЩ - английски - NLM (National Library of Medicine)

medipromtech, llc - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m) - antiseptic - hand sanitizer to decrease bacteria on the skin • recommended for repeated use • for use when soap and water are not available

САЩ - английски - NLM (National Library of Medicine)

macleods pharmaceuticals limited - pyrazinamide (unii: 2kni5n06ti) (pyrazinamide - unii:2kni5n06ti) - pyrazinamide is indicated for the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents. (the current recommendation of the cdc for drug- susceptible disease is to use a six-month regimen for initial treatment of active tuberculosis, consisting of isoniazid, rifampin and pyrazinamide given for 2 months, followed by isoniazid and rifampin for 4 months.* 4 ) (patients with drug-resistant disease should be treated with regimens individualized to their situation. pyrazinamide frequently will be an important component of such therapy.) (in patients with concomitant hiv infection, the physician should be aware of current recommendation of cdc. it is possible these patients may require a longer course of treatment). it is also indicated after treatment failure with other primary drugs in any form of active tuberculosis. pyrazinamide should only be used in conjunction with other effective antituberculous agents. *see recommendations of center for disease cont